Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 5/20 | 0.32 |
| ▸ | GPR6 | P46095 | 2/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CDK7 | P50613 | 1/20 | 0.30 |
| ▸ | CCNH | P51946 | 1/20 | 0.30 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30590717 | 0.82 | EGFR (0.45) | EGFRJAK3BTKCCNA2CDK2 | |
| SCHEMBL26076556 | 0.82 | EGFR (0.45) | EGFRJAK3BTKCCNA2CDK2 | |
| Formic Acid SCHEMBL30595871 | 0.80 | EGFR (0.43) | EGFRJAK3BTKCCNA2CDK2 | |
| SCHEMBL26074894 | 0.80 | EGFR (0.50) | EGFRJAK3BTK | |
| SCHEMBL30590720 | 0.80 | EGFR (0.50) | EGFRJAK3BTK | |
| Formic Acid SCHEMBL30595851 | 0.78 | EGFR (0.48) | EGFRJAK3BTK | |
| SCHEMBL30590738 | 0.76 | EGFR (0.46) | MAPK14MAPK8EGFRBTKCCNA2 | |
| SCHEMBL26074896 | 0.76 | EGFR (0.46) | MAPK14MAPK8EGFRBTKCCNA2 | |
| SCHEMBL29536961 | 0.75 | EGFR (0.47) | MAPK8EGFRJAK3BTKCCNA2 | |
| SCHEMBL26074897 | 0.75 | EGFR (0.47) | MAPK8EGFRJAK3BTKCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | MAPK14 174/4885BRD4 924/4885GPR6 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.